Posts With Tag EYLEA

Explore Regeneron Pharmaceuticals' Q2 2025 financial performance, highlighting $1.39B net income, key products, and ongoing challenges. Investors advised to hold.

Explore Regeneron Pharmaceuticals' Q1 2025 financial performance. Key insights show strong earnings and R&D focus, but declining sales and legal risks warrant a 'Hold' recommendation.